Neuroblastomas are particularly problematic in that some genetic subtypes, such as those exhibiting amplification of the MYCN oncogene or deletion of chromosome 11q, are associated with very poor patient survival in spite of intensive multimodal chemotherapy. Here, MYCN is linked to neuroblastoma.